Since November, there has been good news
that it has been approved for marketing, including pimecrolimus of BrightPharma's wholly-owned subsidiary BrightPharmaceutical, prednisolone of Xinhua Pharmaceutical, and Garnirex acetate API of Sirnaomics.
On the evening of November 21, another pharmaceutical company reported good news
.
Red Sun Pharmaceutical announced that recently, the company received the tosylamamide API "Chemical API Marketing Application Approval Notice" approved and issued by the State Food and Drug Administration; The company's shareholding subsidiary, "Red Sun Jiandakang", received the "Drug Registration Certificate"
of tosylamamide injection approved and issued by the State Food and Drug Administration.
According to reports, toluenesulfonamide injection is an innovative chemical drug for the treatment of solid tumors, which can inhibit tumor growth, shrink tumors and reduce metastasis through intratumor local injection, and quickly alleviate local symptoms of tumors, with a wide range of application, easy to operate and safe characteristics
.
This product is the first approved transfiberobronchoscopic intratumor-injected chemical ablation drug in China, and it is also the first drug
indicated to alleviate severe airway obstruction in adult patients with central non-small cell lung cancer.
Lung cancer is a very high incidence of disease, the incidence of lung cancer in China is very high, mainly non-small cell lung cancer, most of which is central, such patients are often accompanied by severe airway obstruction, surgery and radiotherapy chemotherapy is difficult to alleviate
.
At present, physical ablation (such as laser ablation, freeze-thaw freeze-thaw resection, microwave) is mainly used to remove tumors in the airway to open the lumen and relieve airway obstruction
.
According to the 2020 International Agency for Research on Cancer (IARC), there are 815,000
new cases of lung cancer in China.
There is a huge unmet clinical treatment need
in the majority of patients with central non-small cell lung cancer.
After obtaining the "Drug Registration Certificate" of tosylamamide injection, Hongri Ganyukang, a shareholding subsidiary of Red Sun Pharmaceutical, will help bring more treatment options
to related patients.
It is worth mentioning that tosylamamide APIs are currently only approved by Red Sun Pharmaceutical, and Red Sun Pharmaceutical said that the company obtained the tosylamamide API "Chemical API Marketing Approval Approval Notice", which enriches the company's product categories
.
According to the data, Red Sun Pharmaceutical has a prominent market position in the pharmaceutical industry, and after years of development, it has now become a high-tech pharmaceutical and health industry cluster
integrating investment and financing, research and development, production and sales across many fields such as traditional Chinese medicine formula granules, finished drugs, medical devices, raw and auxiliary materials, medical and health services, and drug and device intelligent supply chain.
According to the third quarter report of 2022, the company's operating income in the first three quarters reached 4.
900 billion yuan, a year-on-year decrease of 10.
68%; The net profit attributable to shareholders of the listed company reached 470 million yuan, down 26.
15%.
It is mainly affected
by the environment.
However, the company's R&D investment in the first three quarters is still strong, and the third quarterly report shows that the company's R&D expenses in the first three quarters were 176 million yuan, an increase of 52.
06%
over the same period last year.
At the same time, sales expenses were 1.
630 billion yuan, a year-on-year decrease of 4.
79%; 30.
9116 million yuan, down 1.
15% year-on-year; Financial expenses were 30.
7571 million yuan, down 19.
92%
from the same period last year.
With continuous investment in innovation and research and development, the company continues to reap innovative results
.
At present, it has 5 Class 1 new drugs with innovative drugs in the field of severe disease, such as KB, anti-tumor PD-L1, more than 30 research projects, more than 5 projects that have been declared for CDE and waiting for review, 2 clinical research stages, and more than 500 effective patents
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
